SLC5A2 and diabetic kidney disease: Specifically, sodium-glucose cotransporter 2 inhibitors, nonsteroidal selective mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide 1 receptor agonists have demonstrated significant cardiorenal benefits in patients with DKD.26, , –29 However, each line of treatment has its own limitations, adverse reactions, and contraindications, as well as added associated costs which limit their use.28,30, , , , , , , –38 In addition, there is residual risk of DKD leading to progression to ESKD despite all abovementioned treatment regimens.